Climb Bio, Inc.
Business
Climb Bio is a clinical-stage biotechnology company developing monoclonal antibodies to treat immune-mediated diseases. Its lead product, budoprutug, is an anti-CD19 antibody in Phase 2 trials for primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. CLYM116, an anti-APRIL antibody licensed from Mabworks, is in Phase 1 development for IgA nephropathy. The company acquired budoprutug assets from Acelyrin through a Tenet Medicines acquisition and operates with a clinical pipeline focused on B-cell-targeted therapies.
Summary from 10-K filed 2026-03-05
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Acquired in-process research and development, related party | 0 | 52 | — | — | — | |
| Research and development expense | 47 | 14 | 15 | 26 | 23 | |
| General and administrative | 21 | 16 | 25 | 19 | 12 | |
| Total operating expenses | 68 | 82 | 40 | 45 | 36 | |
| Total loss from operations | −68 | −82 | −40 | −45 | −36 | |
| Foreign currency loss | −291,000 | −9,000 | — | — | — | |
| Interest income | 8 | 8 | — | — | — | |
| Total other income (expense) | 8 | 8 | 5 | −109,000 | −12 | |
| Net loss | −60 | −74 | −35 | −45 | −47 | |
| Net loss per share, diluted | −0.88 | −1.53 | −1.3 | −1.72 | −4.24 | |
| Net loss per share, basic | −0.88 | −1.53 | −1.3 | −1.72 | −4.24 | |
| Weighted-average number of shares used to compute net loss per share, diluted | 68 | 48 | 27 | 26 | 12 | |
| Weighted-average number of shares used to compute net loss per share, basic | 68 | 48 | 27 | 26 | 12 | |
| Unrealized gain on marketable securities | 412,000 | 25,000 | — | — | — | |
| Comprehensive loss | −59 | −74 | −35 | −45 | −48 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 36 | 87 | 93 | 44 | 47 | |
| Short-term marketable securities | 65 | 64 | 14 | 80 | 90 | |
| Prepaid expenses and other current assets | 5 | 4 | 3 | 11 | 12 | |
| Total current assets | 106 | 155 | 110 | 134 | 148 | |
| Long-term marketable securities | 60 | 62 | 0 | 0 | 25 | |
| Operating lease right-of-use assets | 505,000 | 490,000 | 199,000 | 471,000 | 0 | |
| Property and equipment, net | 288,000 | 199,000 | — | — | — | |
| Other long-term assets | 2 | 16,000 | 15,000 | 128,000 | 70,000 | |
| Total assets | 168 | 217 | 110 | 135 | 173 | |
| Accounts payable | 2 | 705,000 | 66,000 | 750,000 | 1 | |
| Accrued expenses and other current liabilities | 4 | 4 | — | — | — | |
| Operating lease liabilities | 256,000 | 157,000 | 334,000 | 300,000 | 0 | |
| Total current liabilities | 7 | 5 | 3 | 6 | 6 | |
| Operating lease liabilities, net of current portion | 285,000 | 375,000 | 15,000 | 180,000 | 0 | |
| Total liabilities | 7 | 5 | 3 | 6 | 6 | |
| Commitments and contingencies (Note 8) | — | — | — | — | — | |
| Common stock, $0.0001 par value; 250,000,000 shares authorized; 47,766,338 and 67,255,434 shares issued and outstanding at December 31, 2025 and 2024, respectively | 5,000 | 7,000 | 3,000 | 3,000 | 3,000 | |
| Additional paid-in capital | 450 | 442 | 264 | 250 | 243 | |
| Accumulated other comprehensive income | 435,000 | 23,000 | −2,000 | −358,000 | −123,000 | |
| Accumulated deficit | −290 | −230 | −156 | −121 | −76 | |
| Total stockholders' equity | 160 | 212 | 108 | 129 | 167 | |
| Total liabilities and stockholders' equity | 168 | 217 | 110 | 135 | 173 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −60 | −74 | — | — | — | |
| Stock-based compensation expense | 8 | 6 | 13 | 7 | 4 | |
| Non-cash operating lease expense | 201,000 | 220,000 | 405,000 | 443,000 | 0 | |
| Accretion of discounts on marketable securities, net | −2 | −757,000 | −2 | −177,000 | 370,000 | |
| Depreciation and amortization expense | 97,000 | 0 | — | — | — | |
| Unrealized foreign currency transaction (gain) loss | 18,000 | −42,000 | — | — | — | |
| Prepaid expenses and other current assets | −816,000 | 2 | 7 | 945,000 | −10 | |
| Other long-term assets | −2 | −200,000 | — | — | — | |
| Accounts payable | 2 | −963,000 | −686,000 | −653,000 | 318,000 | |
| Accounts payable and accrued liabilities, related party | 0 | −177,000 | 0 | — | — | |
| Accrued expenses and other current liabilities | 372,000 | 1 | — | — | — | |
| Operating lease liabilities | −207,000 | −327,000 | −444,000 | −447,000 | 0 | |
| Long-term liabilities | 0 | −22,000 | — | — | — | |
| Net cash used in operating activities | −54 | −16 | −21 | −37 | −36 | |
| Purchases of property and equipment | −186,000 | 0 | — | — | — | |
| Purchase of marketable securities | −108 | −132 | −58 | −88 | −115 | |
| Maturities of marketable securities | 111 | 21 | 127 | 122 | 0 | |
| Issuance of promissory loan in connection with asset acquisition | 0 | −5 | — | — | — | |
| Cash paid in connection with asset acquisition, net of cash received | 0 | −5 | — | — | — | |
| Net cash provided by (used in) investing activities | 3 | −121 | 69 | 34 | −115 | |
| Proceeds from exercise of stock options | 65,000 | 11 | — | — | — | |
| Pre-funded warrant issuance costs | −86,000 | 0 | — | — | — | |
| Proceeds from issuance of common stock in private placement, net of issuance costs | 0 | 120 | — | — | — | |
| Net cash provided by (used in) financing activities | −21,000 | 131 | 841,000 | 0 | 177 | |
| Effect of exchange rate changes on cash and cash equivalents | 0 | 42,000 | 304,000 | −408,000 | 245,000 | |
| Net change in cash and cash equivalents | −52 | −6 | 50 | −3 | 26 | |
| Issuance of common stock in exchange for in-process research and development | 0 | 42 | — | — | — | |
| Settlement of promissory loan in connection with asset acquisition | 0 | 5 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Climb Bio, Inc.'s CIK number?
Climb Bio, Inc.'s SEC CIK number is 0001768446 (1768446). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Climb Bio, Inc.'s SEC filings?
All of Climb Bio, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Climb Bio, Inc. last report earnings?
Climb Bio, Inc. (CLYM) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-210295). This is Climb Bio, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Climb Bio, Inc.'s most recent earnings 8-K?
Climb Bio, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001193125-26-210295. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Climb Bio, Inc.'s latest earnings 8-K →
Look up any company's CIK number →